GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (LSE:VRCI) » Definitions » ROA %

Verici Dx (LSE:VRCI) ROA % : -27.54% (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Verici Dx ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Verici Dx's annualized Net Income for the quarter that ended in Jun. 2024 was £-2.12 Mil. Verici Dx's average Total Assets over the quarter that ended in Jun. 2024 was £7.70 Mil. Therefore, Verici Dx's annualized ROA % for the quarter that ended in Jun. 2024 was -27.54%.

The historical rank and industry rank for Verici Dx's ROA % or its related term are showing as below:

LSE:VRCI' s ROA % Range Over the Past 10 Years
Min: -84.7   Med: -78.3   Max: -49.17
Current: -49.91

During the past 4 years, Verici Dx's highest ROA % was -49.17%. The lowest was -84.70%. And the median was -78.30%.

LSE:VRCI's ROA % is ranked worse than
82.3% of 226 companies
in the Medical Diagnostics & Research industry
Industry Median: -4.83 vs LSE:VRCI: -49.91

Verici Dx ROA % Historical Data

The historical data trend for Verici Dx's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx ROA % Chart

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROA %
- -49.17 -84.70 -78.30

Verici Dx Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
ROA % Get a 7-Day Free Trial -67.79 -70.77 -87.22 -82.30 -27.54

Competitive Comparison of Verici Dx's ROA %

For the Diagnostics & Research subindustry, Verici Dx's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verici Dx's ROA % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's ROA % distribution charts can be found below:

* The bar in red indicates where Verici Dx's ROA % falls into.



Verici Dx ROA % Calculation

Verici Dx's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-6.9/( (11.744+5.88)/ 2 )
=-6.9/8.812
=-78.30 %

Verici Dx's annualized ROA % for the quarter that ended in Jun. 2024 is calculated as:

ROA %=Net Income (Q: Jun. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Jun. 2024 ))/ count )
=-2.12/( (5.88+9.515)/ 2 )
=-2.12/7.6975
=-27.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Jun. 2024) net income data. ROA % is displayed in the 30-year financial page.


Verici Dx  (LSE:VRCI) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Jun. 2024 )
=Net Income/Total Assets
=-2.12/7.6975
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-2.12 / 5.248)*(5.248 / 7.6975)
=Net Margin %*Asset Turnover
=-40.4 %*0.6818
=-27.54 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2024) net income data. The Revenue data used here is two times the semi-annual (Jun. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Verici Dx ROA % Related Terms

Thank you for viewing the detailed overview of Verici Dx's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Verici Dx Business Description

Traded in Other Exchanges
Address
19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines